The Top Line Fierce Life Sciences

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.  

This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight key trends and share some of the biggest changes at the top and bottom of the rankings year over year.  

To learn more about the topics in this episode:  


The top 20 pharma companies by 2023 revenue
The top 20 pharma companies by 2022 revenue

 
See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce.

This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our biannual Drug Names tournament.

The editors discuss what makes a company or drug name tick, what to steer clear of, and how the entire competition played out. 

To learn more about the topics in this episode: 


#FierceMadness: AstraZeneca and Ionis cruise to victory as Wainua trounces Lilly's Mounjaro for the tournament win
#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED
See omnystudio.com/listener for privacy information.

Jeff Beck of BioCare offers his insight on patient-centric models, complex therapies, data needs, seamless product access and much more.

This week on "The Top Line," we explore biopharma layoffs in the first quarter of 2024. 

Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. With a notable number of layoff rounds marking the start of the year, they examine the factors behind this ongoing challenge while also highlighting positive industry developments.

To learn more about the topics in this episode: 


No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis
Fierce Biotech Layoff Tracker 2024
See omnystudio.com/listener for privacy information.

This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged.  

Join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of the Peripheral Vascular Intervention & CLI Program at Rush University Medical Center. They discuss the hidden dangers of PAD, and Dr. Madassery emphasizes the importance of early detection. He also discusses the launch of the PAD Pulse Alliance, a collaborative effort among vascular health experts aimed at raising awareness, improving early detection and reducing amputation rates. 

To learn more about the topics in this episode: 


Philips-supported campaign wants Americans to 'get a pulse on PAD' amid ignorance of the disease
Johnson & Johnson 'Save Legs. Change Lives.' campaign brings PAD amputation awareness to Black community
Bayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery

 
See omnystudio.com/listener for privacy information.

This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry.

Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. They also discuss the details of the special report and share some of the stories behind the numbers. 

To learn more about the topics in this episode:  


Biotech's top money raisers of 2023
Fierce Biotech Fundraising Tracker 2024
Fierce Biotech Fundraising Tracker 2023

 
See omnystudio.com/listener for privacy information.